Booklet updates: Leukemia

The following drug updates are listed by booklet title. This information is not found in the current version of these booklets, as these treatments were not FDA approved at the time the books were published. 

Acute Lymphoblastic Leukemia (ALL) in Adults

Acute Lymphoblastic Leukemia (ALL) in Children and Teens

 The ALL Guide: Information for Patients and Caregivers

• In November 2024, the Food and Drug Administration (FDA) approved revumenib (Revuforj®) for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.
• In November 2024, the Food and Drug Administration (FDA) approved obecabtagene autoleucel (Aucatzyl®) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
• In June 2024, the Food and Drug Administration (FDA) expanded the indication of blinatumomab (Blincyto®) to include the treatment of adult and pediatric patients one month and older with:
  • CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.  
  • Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL).  
  • CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.
• As of June 2024, Erwinaze® (asparaginase erwinia chrysanthemi) has been discontinued. Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) is available as a treatment option.

Acute Myeloid Leukemia (AML) in Adults: In Detail

Acute Myeloid Leukemia in Children and Teens: In Detail

AML: The Basics

• In May 2026, the Food and Drug Administration (FDA) approved decitabine and cedazuridine (Inqovi®) in combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
• In November 2025, the Food and Drug Administration (FDA) approved ziftomenib (Komzifti™) to treat adults with acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM1) mutation whose AML has come back or did not improve after previous treatment(s) and who have no other satisfactory treatment options.
• In November 2025, the Food and Drug Administration (FDA) expanded the indication of Revumenib (Revuforj®) to include the treatment of adults and children 1 year and older with acute myeloid leukemia with a nucleophosmin 1 (NPM1) mutation whose disease has come back or has not improved after previous treatment(s) and who have no other satisfactory treatment options.

Chronic Lymphocytic Leukemia: In Detail​ 

CLL: The Basics

No Updates

Chronic Myeloid Leukemia: In Detail​ 

CML: The Basics

No Updates

<< Previous Page